Online inquiry

IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15403MR)

This product GTTS-WQ15403MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets HAVCR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_032782.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84868
UniProt ID Q8TDQ0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15403MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10841MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ8246MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ6895MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ3990MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ15399MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ6790MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ5182MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ13570MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRX-302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW